Syros Prescribed drugs, Inc. (NASDAQ:SYRS – Get Free Report) Director Nancy A. Simonian bought 37,070 shares of the corporate’s inventory in a transaction that occurred on Monday, December 2nd. The inventory was bought at a median value of $0.27, for a complete worth of $10,008.90. Following the transaction, the director now instantly owns 4,000 shares of the corporate’s inventory, valued at roughly $1,080. The commerce was a 90.26 % lower of their possession of the inventory. The sale was disclosed in a doc filed with the Securities & Trade Fee, which is accessible by this link.
Syros Prescribed drugs Inventory Down 1.2 %
NASDAQ SYRS opened at $0.25 on Thursday. The corporate has a present ratio of two.25, a fast ratio of two.25 and a debt-to-equity ratio of 1.97. Syros Prescribed drugs, Inc. has a twelve month low of $0.18 and a twelve month excessive of $8.17. The inventory has a fifty day easy shifting common of $1.58 and a 200-day easy shifting common of $3.29.
Syros Prescribed drugs (NASDAQ:SYRS – Get Free Report) final introduced its quarterly earnings information on Thursday, October thirty first. The corporate reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. Throughout the identical interval within the earlier 12 months, the agency posted ($1.35) earnings per share. On common, sell-side analysts anticipate that Syros Prescribed drugs, Inc. will publish -2.94 earnings per share for the present 12 months.
Institutional Inflows and Outflows
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year…
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator – the “Buffett indicator” – just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
A number of institutional buyers have lately added to or decreased their stakes in SYRS. Vanguard Group Inc. boosted its stake in shares of Syros Prescribed drugs by 21.3% within the first quarter. Vanguard Group Inc. now owns 928,046 shares of the corporate’s inventory valued at $4,965,000 after shopping for a further 163,234 shares within the final quarter. Virtu Monetary LLC bought a brand new stake in shares of Syros Prescribed drugs within the first quarter valued at roughly $64,000. Acadian Asset Administration LLC boosted its stake in shares of Syros Prescribed drugs by 101.5% within the second quarter. Acadian Asset Administration LLC now owns 34,578 shares of the corporate’s inventory valued at $178,000 after shopping for a further 17,416 shares within the final quarter. Certuity LLC bought a brand new stake in Syros Prescribed drugs in the course of the second quarter price $109,000. Lastly, GSA Capital Companions LLP bought a brand new stake in Syros Prescribed drugs in the course of the third quarter price $34,000. Institutional buyers and hedge funds personal 91.47% of the corporate’s inventory.
Wall Avenue Analysts Forecast Progress
A number of analysis analysts lately commented on SYRS shares. HC Wainwright reissued a “impartial” ranking and issued a $1.00 value goal (down from $6.00) on shares of Syros Prescribed drugs in a analysis be aware on Wednesday, November thirteenth. TD Cowen reissued a “maintain” ranking on shares of Syros Prescribed drugs in a analysis be aware on Wednesday, November thirteenth. Brookline Capital Administration reissued a “maintain” ranking on shares of Syros Prescribed drugs in a analysis be aware on Wednesday, November thirteenth. StockNews.com initiated protection on Syros Prescribed drugs in a analysis be aware on Friday, November twenty ninth. They issued a “promote” ranking for the corporate. Lastly, JMP Securities reaffirmed a “market carry out” ranking on shares of Syros Prescribed drugs in a analysis be aware on Wednesday, November thirteenth. One analyst has rated the inventory with a promote ranking, 4 have issued a maintain ranking and one has given a purchase ranking to the corporate. Based on MarketBeat.com, Syros Prescribed drugs presently has a consensus ranking of “Maintain” and a median goal value of $3.33.
Check Out Our Latest Stock Analysis on SYRS
About Syros Prescribed drugs
Syros Prescribed drugs, Inc, a biopharmaceutical firm, focuses on the event of therapy for hematologic malignancies. The corporate’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Part III medical trial for genomically outlined subset of sufferers with myelodysplastic syndrome and Part II medical trial for sufferers with acute myeloid leukemia; SY-2101, a novel oral type of arsenic trioxide for treating sufferers with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Part I medical trial in sufferers with choose superior stable tumors.
Featured Articles
This prompt information alert was generated by narrative science expertise and monetary information from InsiderTrades.com with the intention to present readers with the quickest and most correct reporting. This story was reviewed by InsiderTrades.com’s editorial group previous to publication. Please ship any questions or feedback about this story to [email protected].
